NYSE$STVN
Stevanato Group S.p.A. · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Reported revenue of €256.6 million for the first quarter of 2025
Stevanato Group reported a 9% increase in revenue for the first quarter of 2025, reaching €256.6 million, primarily driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment. Gross profit and operating profit margins also improved. The company maintained its full-year revenue guidance but lowered its adjusted EBITDA and adjusted diluted EPS guidance to reflect the estimated impact of recently announced tariffs.
- Revenue increased by 9% to €256.6 million in Q1 2025 compared to the prior year.
- The Biopharmaceutical and Diagnostic Solutions segment saw 11% revenue growth, offsetting a decline in the Engineering segment.
- Gross profit margin improved by 80 basis points to 27.2%, and adjusted operating profit margin increased to 14.3%.
- Full-year 2025 guidance for adjusted EBITDA and adjusted diluted EPS was updated to reflect the estimated impact of tariffs.
Headline financials
Revenue & EPS history
Stevanato Group · Revenue · Quarterly
$278M
Revenue by segment
Stevanato Group · $518M total across 3 segments · Q4 2025
- Biopharmaceutical and Diagnostic Solutions$307M+9.9%59.3%
- High-value solutions$171M+30.5%33.0%
- Engineering$39.4M-23.0%7.6%
Forward guidance
For fiscal year 2025, Stevanato Group maintains its revenue guidance of €1,160 million to €1,190 million. However, guidance for adjusted EBITDA is updated to €288.5 million to €301.8 million, and adjusted diluted EPS to €0.50 to €0.54, reflecting an estimated €4.5 million tariff impact on operating profit.
Tailwinds
- Maintaining full-year revenue guidance (€1,160 million - €1,190 million).
- Continued strong demand for high-value solutions expected.
- Expected continued improvements and scaling at Latina and Fishers facilities.
- Gradual stabilization expected in vial demand as destocking fades.
- Business fundamentals are strong with favorable secular tailwinds.
Headwinds
- Lowering adjusted EBITDA guidance (€288.5 million - €301.8 million) due to estimated tariffs.
- Lowering adjusted diluted EPS guidance (€0.50 - €0.54) due to estimated tariffs.
- Estimated tariff impact of approximately €4.5 million on operating profit.
- Ongoing focus on completing legacy projects in the Engineering segment.
- Anticipating absorption of price increases from suppliers due to tariffs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
+1.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+3.0%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+22.3%
Q2 2021
Best reaction
-18.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +10.0% | +1.9% | -10.3% | |
| Q3 2025 | -1.7% | -3.3% | -11.6% | |
| Q2 2025 | -9.6% | -7.6% | -9.9% | |
| Q1 2025 | +2.9% | +12.0% | +8.9% | |
| Q4 2024 | +8.6% | +8.8% | +10.5% | |
| Q3 2024 | +16.4% | +12.4% | +3.9% | |
| Q2 2024 | +4.4% | +8.5% | +13.8% | |
| Q1 2024 | -18.9% | -20.7% | -30.8% | |
| Q4 2023 | -11.3% | -14.1% | -12.4% | |
| Q3 2023 | -5.9% | -2.5% | -3.5% | |
| Q2 2023 | +2.5% | +5.6% | +6.3% | |
| Q1 2023 | -3.3% | -1.5% | +2.6% | |
| Q4 2022 | +13.7% | +5.2% | +16.0% | |
| Q3 2022 | +0.4% | +9.1% | +18.0% | |
| Q2 2022 | +4.6% | -3.4% | -5.9% | |
| Q1 2022 | +0.7% | +8.7% | +11.2% | |
| Q4 2021 | -1.4% | -4.2% | +21.9% | |
| Q3 2021 | -8.7% | -11.2% | -4.8% | |
| Q2 2021 | +22.3% | +27.0% | +33.8% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro